ArticleScientific reports2026
Urine bis(Monoacylglycerol)Phosphate and risk of freezing of gait in parkinson's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Urine bis(monoacylglycero)phosphate (BMP) levels are reportedly increased in GBA variants carriers of patients with Parkinson's disease (PD). Freezing of gait (FOG) is a common PD patients, we aimed to evaluate the association of urinary BMP with the risk of FOG development in a large PD cohort. A total of 354 PD patients from the Parkinson's Progression Markers Initiative (PPMI) were included in this study, and urinary BMPs, including total di-22:6-BMP and 2,2'-di-22:6-BMP, were evaluated at baseline. They were followed up for up to 5 years to examine the progression of FOG. The cumulative incidence of FOG and risk factors for FOG were assessed via Kaplan‒Meier and Cox regression analyses. At baseline, the future FOG group presented higher baseline total di-22:6-BMP levels and 2,2'-di-22:6-BMP levels. During follow-up, baseline urinary 2,2'-di-22:6-BMP was associated with the progression of FOG. In the multivariable Cox analysis, urinary 2,2'-di-22:6-BMP remained an independent predictor of FOG (HR 1.030; 95% CI 1.010-1.051; p = 0.010). In the subgroup analyses, the "high-level" group had a significantly greater incidence of FOG than the "low-level" group and GBA variants independently increased the risk of FOG in the "high-level" group.We found that baseline urinary 2,2'-di-22:6-BMP was a predictor of FOG development in early PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.